AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35775211
Drug: Post-treatment physical
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment physical activity scores after three months of BC therapy
Trial: 35775211
Drug: Six-minute walk
RxNorm normalized name: Tagetes minuta flower oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six-minute walk distance (6MWD) pre-treatment
Trial: 35775211
Drug: Six-minute walk
RxNorm normalized name: Tagetes minuta flower oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six-minute walk distance (6MWD) post-treatment
Trial: 35775211
Drug: Left ventricular
RxNorm normalized name: DRESSING,VENTRICULAR ASSIST DEVICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Left ventricular ejection fraction (LVEF) pre-treatment
Trial: 35775211
Drug: Left ventricular
RxNorm normalized name: DRESSING,VENTRICULAR ASSIST DEVICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Left ventricular ejection fraction (LVEF) post-treatment
Trial: 35775390
Drug: CD34 cell
RxNorm normalized name: Autologous CD34+ cells encoding βA-T87Q-Globin gene
DrugBank: Betibeglogene autotemcel (DB16900)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD34 cell therapy
Trial: 35776185
Drug: Doxycycline 50
RxNorm normalized name: doxycycline 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 50 mg once daily
Trial: 35776185
Drug: Doxycycline 100
RxNorm normalized name: doxycycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg once daily
Trial: 35776269
Drug: SB5-HC (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB5-HC (40 mg/0.4 ml)
Trial: 35776269
Drug: SB5-LC (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB5-LC (40 mg/0.8 ml)
Trial: 35776489
Drug: Daily meditation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily meditation via Calm app
Trial: 35777186
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg Q3W for up to 35 cycles (∼2 years)
Trial: 35777697
Drug: Motivational Enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational Enhancement Therapy (MET) 'check-ups'
Trial: 35778568
Drug: Selective agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective agonist of CB2r (JWH133)
Trial: 35778674
Drug: Preoperative frailty
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative frailty domains (medication use, living situation, mobility, gait speed, Nagi's physical functioning, preoperative HRQL)
Trial: 35779095
Drug: Polyvalent antigen-KLH
RxNorm normalized name: Polyvalent antigen-KLH conjugate vaccine
DrugBank: Polyvalent antigen-KLH conjugate vaccine (DB17565)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyvalent antigen-KLH plus OPT-821 vaccine construct and bevacizumab
Trial: 35779659
Drug: TXR 140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXR 140 μg
Trial: 35779659
Drug: TXR 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXR 200 μg
Trial: 35780092
Drug: Norepinephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine infusion in SOMATO-treated patients
Trial: 35780092
Drug: Norepinephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine infusion in SOMATO-untreated patients
Trial: 35780095
Drug: ePRO follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ePRO follow-up pathway with automated 3-monthly reminders for ePRO questionnaire and blood tests.
Trial: 35780243
Drug: Troriluzole (BHV-4157)
RxNorm normalized name: Troriluzole
DrugBank: Troriluzole (DB15079)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troriluzole (BHV-4157) 420 mg total daily dose in combination with nivolumab 240 mg IV every 2 weeks
Trial: 35780243
Drug: Troriluzole monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troriluzole monotherapy (lead-in period)
Trial: 35782623
Drug: Oral lucerastat
RxNorm normalized name: Lucerastat
DrugBank: Lucerastat (DB14872)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lucerastat twice daily for 6 months
Trial: 35782751
Drug: Paclitaxel (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (80 mg/m2)
Trial: 35782954
Drug: Prebiotic fiber
RxNorm normalized name: Benefiber Prebiotic Fiber
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prebiotic fiber supplement (12 g daily)
Trial: 35782954
Drug: Placebo (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (12 g daily)
Trial: 35783822
Drug: Colchicine 0.6
RxNorm normalized name: colchicine 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 0.6 mg po twice daily for 30 days plus standard of care
Trial: 35784017
Drug: Paracetamol and
RxNorm normalized name: Paracetamol and tramadol only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol and opioids
Trial: 35784545
Drug: Thyroid hormone
RxNorm normalized name: Thyroid hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid hormone sensitivity (measured by TSHI, TFQI, TSHI, TT4RI, PTFQI, FT3/FT4)
Trial: 35784545
Drug: Thyroid hormone
RxNorm normalized name: Thyroid hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid hormone sensitivity (in females)
Trial: 35784545
Drug: Thyroid hormone
RxNorm normalized name: Thyroid hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid hormone sensitivity (in patients aged over 60 years)
Trial: 35784641
Drug: Adipose-derived MSC
RxNorm normalized name: human adipose preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adipose-derived MSC infusions (1 × 10)
Trial: 35785613
Drug: Peer support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer support services integrated into primary care for OUD treatment.
Trial: 35785613
Drug: Buprenorphine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine treatment for OUD.
Trial: 35786544
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ACC and PPG modalities
Trial: 35787784
Drug: PI3Kα inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PI3Kα inhibitor alpelisib
Trial: 35787831
Drug: edoxaban (3-month
FDA approved: no
EMA approved: no
PMDA approved: no
Description: edoxaban (3-month treatment)
Trial: 35788722
Drug: Niraparib 200
RxNorm normalized name: niraparib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib 200 mg once daily in 28-day cycles
Trial: 35789068
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (most common treatment regimen, 24.8%)
Trial: 35789261
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil fumarate (TDF) therapy during late pregnancy
Trial: 35789594
Drug: JOTROL (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JOTROL (a highly bioavailable resveratrol preparation)
Trial: 35790143
Drug: Blinatumomab (9-28
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinatumomab (9-28 μg/day for adults; 5-15 μg/m2/day for pediatrics)
Trial: 35790315
Drug: Ceralasertib (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceralasertib (240 mg two times a day) plus durvalumab (1500 mg) every 4 weeks
Trial: 35790332
Drug: Neotree e-health
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neotree e-health solution (android app with data visualisation)
Trial: 35790651
Drug: Antifibrotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antifibrotic therapy (specifics not provided)
Trial: 35791625
Drug: semaglutide 2.4
RxNorm normalized name: semaglutide 2.4 MG in 0.75 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: semaglutide 2.4 mg single-dose pen-injector
Trial: 35792924
Drug: PegaGen (pegfilgrastim)
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: PegaGen (pegfilgrastim) administered once per cycle, with a single 6 mg dose injected in 99.17% of cycles.
Trial: 35793925
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of HPV E4 and p16
Trial: 35793990
Drug: DA-8010 5
RxNorm normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DA-8010 5 mg
Trial: 35793990
Drug: DA-8010 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DA-8010 2.5 mg
Trial: 35794343
Drug: BACE inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BACE inhibitor verubecestat
Trial: 35794614
Drug: Regional anesthesia
RxNorm normalized name: ACL6SP45 REGIONAL ANESTHESIA KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regional anesthesia techniques (specifically double injection erector spinae plane block)
Trial: 35794614
Drug: Double injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double injection erector spinae plane block
Trial: 35794623
Drug: Nintedanib 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib 200 mg bid in combination with pembrolizumab 200 mg Q3W
Trial: 35794623
Drug: Nintedanib 150
RxNorm normalized name: nintedanib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib 150 mg bid in combination with pembrolizumab 200 mg Q3W
Trial: 35794623
Drug: Nintedanib 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib 200 mg bid
Trial: 35794623
Drug: Nintedanib and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib and pembrolizumab therapy
Trial: 35795231
Drug: Italian version
RxNorm normalized name: ALLERGENIC EXTRACT, ITALIAN RYEGRASS POLLEN
DrugBank: Lolium perenne subsp. multiflorum pollen (DB10964)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Italian version of the LARS score (tested twice)
Trial: 35795367
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no treatment of CSA)
Trial: 39307144
Drug: Rodatristat ethyl
RxNorm normalized name: Rodatristat ethyl
DrugBank: Rodatristat ethyl (DB18479)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rodatristat ethyl 300 mg twice daily
Trial: 39307144
Drug: Rodatristat ethyl
RxNorm normalized name: Rodatristat ethyl
DrugBank: Rodatristat ethyl (DB18479)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rodatristat ethyl 600 mg twice daily
Trial: 35795629
Drug: 3D Virtual
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3D Virtual Reality training for chemotherapy administration
Trial: 35795849
Drug: Intraovarian injection
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRAOVARIAN LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraovarian injection of platelet-rich plasma (PRP) (1.5 ml) with an average of 12 injections per ovary.
Trial: 35796785
Drug: Bendamustine hydrochloride
RxNorm normalized name: Bendamustine Hydrochloride
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bendamustine hydrochloride (10-min dosing)
Trial: 35796785
Drug: Rituximab 375
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 375 mg/m
Trial: 35797012
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy with pertuzumab (840 mg first cycle, 420 mg subsequent cycles), atezolizumab (1200 mg), docetaxel (75 mg/m2), and trastuzumab (600 mg subcutaneous) every 3 weeks for 6 cycles.
Trial: 35797012
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy for patients with pCR: 12 cycles of atezolizumab, trastuzumab, and pertuzumab every 3 weeks after surgery.
Trial: 35797012
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy for patients without pCR: 14 cycles of atezolizumab (1200 mg) plus trastuzumab emtansine (3.6 mg/kg) every 3 weeks.
Trial: 35797012
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy (overall treatment)
Trial: 35797864
Drug: Chinese medicine
RxNorm normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medicine (CM) treatment
Trial: 35798000
Drug: Homologous mRNA
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homologous mRNA vaccine boosting
Trial: 35798000
Drug: Heterologous mRNA
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heterologous mRNA and Ad26.COV2.S vaccine boosting
Trial: 35798241
Drug: SH-1028 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SH-1028 (200 mg/d orally until disease progression or intolerable toxicity)
Trial: 35798468
Drug: S-1-based treatment
RxNorm normalized name: S-38093 free base
DrugBank: S-38093 (DB16893)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1-based treatment after cardiotoxicity from capecitabine or 5-FU
Trial: 35798468
Drug: S-1-based treatment
RxNorm normalized name: S-38093 free base
DrugBank: S-38093 (DB16893)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1-based treatment
Trial: 35799116
Drug: Elevated serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated serum thyroid-stimulation hormone (TSH) levels
Trial: 35799290
Drug: SABA prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SABA prescription (≥3 canisters)
Trial: 35799290
Drug: SABA prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SABA prescription (≥10 canisters)
Trial: 35799290
Drug: SABA prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SABA prescription and OTC purchase
Trial: 35799394
Drug: Selpercatinib (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selpercatinib (160 mg bid, orally, 28-day cycles)
Trial: 35800017
Drug: Integrated Social
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated Social Cognitive and Behavioral Skill Therapy (ISST)
Trial: 35800360
Drug: Intracoronary reteplase
RxNorm normalized name: reteplase
DrugBank: Reteplase (DB00015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary reteplase (9 mg or 18 mg)
Trial: 35800670
Drug: Two tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tablets of tramadol 37.5 mg/acetaminophen 325 mg ER FDC (DW-0920)
Trial: 35800670
Drug: One tablet
RxNorm normalized name: Hydone Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet of tramadol 75 mg/acetaminophen 650 mg
Trial: 35801187
Drug: Alirocumab (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab (150 mg every 2 weeks for 12 weeks)
Trial: 35801558
Drug: Criterion-based, standardised,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Criterion-based, standardised, two-phase therapy protocol
Trial: 35801762
Drug: Water-soluble contrast
RxNorm normalized name: WATER SOLUBLE BASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water-soluble contrast agent (iohexol) swallowing study (WSS)
Trial: 35801795
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal oxygen at a flow rate of 2 L kg-1 min-1
Trial: 35802001
Drug: Web-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based therapy (mixed-method cognitive behavioral therapy)
Trial: 35802063
Drug: Sofosbuvir-velpatasvir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir-velpatasvir (400 mg/100 mg) daily for 12 weeks
Trial: 36967448
Drug: Dexamethasone intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone intravitreal implant (DEX)
Trial: 35802402
Drug: Friendship Bench
RxNorm normalized name: beach strawberry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Friendship Bench (FB) program, a problem-solving therapy (PST)-based program adapted for use among people living with HIV on MMT.
Trial: 35802405
Drug: Insulin Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin Glargine U300 (IGlar-300)
Trial: 35802405
Drug: Insulin Degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin Degludec U100 (IDeg-100)
Trial: 35802786
Drug: CPS-specific antibodies
RxNorm normalized name: methylcellulose (1500 CPS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPS-specific antibodies
Trial: 35802786
Drug: Correlation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation of antibody levels
Trial: 35803286
Drug: Mosunetuzumab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosunetuzumab (1 mg on cycle 1 day 1, 2 mg on cycle 1 day 8, 60 mg on cycle 1 day 15 and cycle 2 day 1, 30 mg on day 1 of cycle 3 and onwards)
Trial: 35803294
Drug: CEND-1 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEND-1 monotherapy
Trial: 35803731
Drug: Woven EndoBridge
RxNorm normalized name: Arthricare for Women Moisturizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Woven EndoBridge (WEB) device treatment
Trial: 35803835
Drug: Olaparib treatment
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib treatment in gBRCAm cohort
Trial: 35803835
Drug: Olaparib treatment
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib treatment in sBRCAm cohort
Trial: 35803835
Drug: Olaparib treatment
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib treatment in HRD-positive cohort
Trial: 35803835
Drug: Olaparib treatment
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib treatment in HRD-negative cohort
Trial: 39361218
Drug: Radium-223 therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radium-223 therapy
Trial: 35804188
Drug: Patients who
RxNorm normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who discontinued radium-223 therapy
Trial: 35804294
Drug: Eptinezumab 300
RxNorm normalized name: Eptinezumab
DrugBank: Eptinezumab (DB14040)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eptinezumab 300 mg intravenous every 12 weeks for up to 8 doses
Trial: 35804385
Drug: Bushen Culuan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bushen Culuan Decoction 13 g three times a day for 14 days and clomiphene citrate placebo tablets 50 mg once a day for 5 days starting on day 5 of every menstrual period.
Trial: 35804385
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate tablets 50 mg once a day for 5 days starting on day 5 of every menstrual period (control group).
Trial: 35804404
Drug: Topical sirolimus
RxNorm normalized name: sirolimus Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical sirolimus solution (1 mg/mL) applied once daily for 24 weeks
Trial: 35804454
Drug: Standard treatment:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment: rifampicin plus clarithromycin for 8 weeks
Trial: 35804454
Drug: Investigational treatment:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational treatment: rifampicin plus clarithromycin plus amoxicillin/clavulanate for 4 weeks
Trial: 35805716
Drug: Acute triiodothyronine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute triiodothyronine (T3) treatment
Trial: 35805716
Drug: T3 administration
RxNorm normalized name: T3
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: T3 administration
Trial: 35806269
Drug: Non-surgical periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical periodontal therapy with adjunctive systemic antibiotics (amoxicillin/metronidazole)
Trial: 35808998
Drug: tDCS (transcranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tDCS (transcranial direct current stimulation) combined with prolonged exposure (PE) therapy
Trial: 35810079
Drug: Rescue subcutaneous
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue subcutaneous (s.c.) progesterone therapy (25 mg)
Trial: 35810079
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal progesterone tablet plus i.m. progesterone (control group)
Trial: 35810296
Drug: Sucroferric oxyhydroxide
RxNorm normalized name: Sucroferric Oxyhydroxide
DrugBank: Iron sucrose (DB09146)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucroferric oxyhydroxide (SO) titrated to a goal serum phosphate of <5.5 mg/dL
Trial: 35810553
Drug: Nazartinib 150
RxNorm normalized name: Lazertinib
DrugBank: Lazertinib (DB16216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nazartinib 150 mg once daily
Trial: 35810555
Drug: Cyclic fasting-mimicking
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic fasting-mimicking diet (FMD) combined with standard anticancer therapies